Edition:
United States

Manas Mishra

Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebuke

2:35pm EST

Catalyst Pharmaceuticals Inc, rebuked by U.S. Senator Bernie Sanders for its high drug prices, on Thursday defended its $375,000 treatment for a rare disease, saying the price was in line with similar products in the industry.

CVS profit miss, rebate questions send shares tumbling 8 percent

Feb 20 2019

CVS Health Corp on Wednesday forecast 2019 profit well below Wall Street estimates due to weakness in its pharmacy business that serves long-term care facilities and slower than anticipated growth in drug prices, sending shares down 8 percent.

Intercept's fatty liver drug meets late-stage main goal, shares soar

Feb 19 2019

Intercept Pharmaceuticals Inc said on Tuesday its treatment in patients with a progressive fatty liver disease showed an improvement in scarring on the organ, taking the drug a step closer to approval and sending the company's shares surging 25 percent.

Merck, Pfizer drug combo extends kidney cancer survival: study

Feb 16 2019

A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday.

Johnson & Johnson to buy surgical robotics firm Auris for $3.4 billion

Feb 13 2019

Johnson & Johnson said on Wednesday it would buy Auris Health Inc for $3.4 billion in cash, gaining access to the privately held company's surgical robotic scope used in respiratory procedures and the detection of lung cancer.

UniQure gene therapy shows promising result in mid-stage trial

Feb 08 2019

Gene therapy company UniQure NV said on Friday its treatment for hemophilia B increased the levels of a protein that helps in blood clotting after 12 weeks in a relatively small study.

Health insurer Humana's full-year profit forecasts disappoints

Feb 06 2019

Humana Inc's full-year profit forecast came in shy of analysts' estimates on Wednesday as its Medicare Prescription drug plans remained under pressure and said it expects 2019 margins in the fast-growing business to fall short of its own targets.

FDA approves cheaper Botox rival to treat frown lines

Feb 04 2019

(This Feb. 1 story has been corrected to remove reference to dosage in paragraph 7)

World News